Infecções por Vibrio não colérico

Referências

Principais artigos

Dechet AM, Yu PA, Koram N, et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. 2008;46:970-976. Resumo

Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005;133:383-391. Resumo

Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med. 2006;166:2117-2123. [Erratum in: Arch Intern Med. 2007;167:194.]Texto completo  Resumo

Halow KD, Harner RC, Fontenelle LJ. Primary skin infections secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg. 1996;183:329-334. Resumo

Kuo YL, Shieh SJ, Chiu HY, et al. Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis. 2007;26:785-792. Resumo

Artigos de referência

1. Farmer JJ, Janda JM, Birkhead K. Chapter 46: Vibrio. In: PR Murray, ed. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press; 2003.

2. Thompson FL, Gevers D, Thompson CC, et al. Phylogeny and molecular identification of vibrios on the basis of multilocus sequence analysis. Appl Environ Microbiol. 2005;71:5107-5115.Texto completo  Resumo

3. Thompson FL, Iida T, Swings J. Biodiversity of vibrios. Microbiol Mol Biol Rev. 2004;68:403-431.Texto completo  Resumo

4. Penland R, Boniuk M, Wilhelmus KR. Vibrio ocular infections on the U.S. Gulf Coast. Cornea. 2000;19:26-29. Resumo

5. Dechet AM, Yu PA, Koram N, et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. 2008;46:970-976. Resumo

6. Igbinosa EO, Okoh AI. Emerging Vibrio species: an unending threat to public health in developing countries. Res Microbiol. 2008;159:495-506. Resumo

7. Martinez-Urtaza J, Huapaya B, Gavilan RG, et al. Emergence of Asiatic Vibrio diseases in South America in phase with El Nino. Epidemiology. 2008;19:829-837. Resumo

8. Wootipoom N, Bhoopong P, Pomwised R, et al. A decrease in the proportion of infections by pandemic Vibrio parahaemolyticus in Hat Yai Hospital, southern Thailand. J Med Microbiol. 2007;56:1630-1638.Texto completo  Resumo

9. Khaira G, Galanis E. Descriptive epidemiology of Vibrio parahaemolyticus and other Vibrio species infections in British Columbia: 2001-2006. Can Commun Dis Rep. 2007;33:12-22.Texto completo  Resumo

10. Public Health Agency of Canada. Public health notice: outbreak of Vibrio parahaemolyticus linked to raw shellfish. October 2015. http://www.phac-aspc.gc.ca/.Texto completo

11. Goarant C, Reynaud Y, Ansquer D, et al. Molecular epidemiology of Vibrio nigripulchritudo, a pathogen of cultured penaeid shrimp (Litopenaeus stylirostris) in New Caledonia. Syst Appl Microbiol. 2006;29:570-580. Resumo

12. Inoue Y, Ono T, Matsui T, et al. Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol. 2008;35:129-139. Resumo

13. Harth E, Matsuda L, Hernández C, et al. Epidemiology of Vibrio parahaemolyticus outbreaks, southern Chile. Emerg Infect Dis. 2009;15:163-168.Texto completo  Resumo

14. Centers for Disease Control and Prevention. National enteric disease surveillance: COVIS annual summary, 2014 - summary of human Vibrio cases reported to CDC, 2014. May 2016. https://www.cdc.gov.Texto completo

15. Food and Drug Administration. FDA investigated multistate outbreak of vibrio parahaemolyticus linked to fresh crab meat imported from Venezuela. September 2018 [internet publication].Texto completo

16. Centers for Disease Control and Prevention. Multistate outbreak of gastrointestinal illnesses linked to oysters imported from Mexico. June 2019 [internet publication].Texto completo

17. Centers for Disease Control and Prevention (CDC), National Enteric Disease Surveillance. Cholera and Other Vibrio Illness (COVIS) annual summary, 2009: summary of human Vibrio cases reported to CDC, 2009. November 2011. http://www.cdc.gov/.Texto completo

18. Hsueh PR, Lin CY, Tang HJ, et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis. 2004;10:1363-1368.Texto completo  Resumo

19. Neill MA, Carpenter CCJ. Chapter 215, Other pathogenic vibrios. In: Mandell GL, Douglas RG, Bennett JE, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 9th ed. Philadelphia, PA: Elsevier, Churchill Livingstone; 2019:2645-2649.e1

20. Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005;133:383-391. Resumo

21. Schmidt U, Chmel H, Cobbs C. Vibrio alginolyticus infections in humans. J Clin Microbiol. 1979;10:666-668.Texto completo  Resumo

22. Patterson TF, Bell SR, Bia FJ. Vibrio alginolyticus cellulitis following coral injury. Yale J Biol Med. 1988;61:507-512.Texto completo  Resumo

23. Gomez JM, Fajardo R, Patino JF, et al. Necrotizing fasciitis due to Vibrio alginolyticus in an immunocompetent patient. J Clin Microbiol. 2003;41:3427-3429.Texto completo  Resumo

24. Opal SM, Saxon JR. Intracranial infection by Vibrio alginolyticus following injury in salt water. J Clin Microbiol. 1986;23:373-374.Texto completo  Resumo

25. Strom MS, Paranjpye RN. Epidemiology and pathogenesis of Vibrio vulnificus. Microbes Infect. 2000;2:177-188. Resumo

26. Miyoshi S. Vibrio vulnificus infection and metalloprotease. J Dermatol. 2006;33:589-595. Resumo

27. Kim K, Kim NJ, Kim SY, et al. Cyclo(Phe-Pro) produced by the human pathogen Vibrio vulnificus inhibits host innate immune responses through the NF-κB pathway. Infect Immun. 2015;83:1150-1161.Texto completo  Resumo

28. Jang HC, Choi SM, Kim HK, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014;9:e101118.Texto completo  Resumo

29. Broberg CA, Calder TJ, Orth K. Vibrio parahaemolyticus cell biology and pathogenicity determinants. Microbes Infect. 2011;13:992-1001.Texto completo  Resumo

30. Zhang L, Orth K. Virulence determinants for Vibrio parahaemolyticus infection. Curr Opin Microbiol. 2013;16:70-77. Resumo

31. de Souza Santos M, Orth K. Intracellular Vibrio parahaemolyticus escapes the vacuole and establishes a replicative niche in the cytosol of epithelial cells. MBio. 2014;5:e01506-14.Texto completo  Resumo

32. Tantillo GM, Fontanarosa M, Di Pinto A, et al. Updated perspectives on emerging vibrios associated with human infections. Lett Appl Microbiol. 2004;39:117-126. Resumo

33. Kumamoto KS, Vukich DJ. Clinical infections of Vibrio vulnificus: a case report and review of the literature. J Emerg Med. 1998;16:61-66. Resumo

34. Janda JM, Powers C, Bryant RG, et al. Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp. Clin Microbiol Rev. 1988;1:245-267.Texto completo  Resumo

35. Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis. 1999;179:275-278. Resumo

36. Hor LI, Chang YK, Chang CC, et al. Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol. 2000;44:871-878. Resumo

37. Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis. 2011;52:788-792.Texto completo  Resumo

38. Vugia DJ, Tabnak F, Newton AE, et al. Impact of 2003 state regulation on raw oyster-associated Vibrio vulnificus illnesses and deaths, California, USA. Emerg Infect Dis. 2013;19:1276-1280.Texto completo  Resumo

39. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143.Texto completo  Resumo

40. Scully EP, Earp BE, Miller AL, Loscalzo J. Just a cut. N Engl J Med. 2016;375:1780-1786 Resumo

41. Hedberg CW, Palazzi-Churas KL, Radke VJ, et al. The use of clinical profiles in the investigation of foodborne outbreaks in restaurants: United States, 1982-1997. Epidemiol Infect. 2008;136:65-72. Resumo

42. Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med. 2006;166:2117-2123. [Erratum in: Arch Intern Med. 2007;167:194.]Texto completo  Resumo

43. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-377.Texto completo  Resumo

44. Chao WN, Tsai CF, Chang HR, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg. 2013;206:32-39. Resumo

45. Daniels NA, MacKinnon L, Bishop R, et al. Vibrio parahaemolyticus infection in the United States, 1973-1998. J Infect Dis. 2000;181:1661-1666. Resumo

46. Gilbert DN, Chambers HF, Saag MS, et al, eds. The Sanford guide to antimicrobial therapy 2021. 51st ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2021.

47. Chuang YC, Liu JW, Ko WC, et al. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother. 1997;41:2214-2217. Resumo

48. Kim SE, Shin SU, Oh TH, et al. Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis. PLoS Negl Trop Dis. 2019 Jun;13(6):e0007478.Texto completo  Resumo

49. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. November 2018 [internet publication].Texto completo

50. Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. August 2018 [internet publication].Texto completo

51. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. December 2018 [internet publication].Texto completo

52. Food and Drug Administration. FDA Drug Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. July 2018 [internet publication]Texto completo

53. Halow KD, Harner RC, Fontenelle LJ. Primary skin infections secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg. 1996;183:329-334. Resumo

54. Kuo YL, Shieh SJ, Chiu HY, et al. Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis. 2007;26:785-792. Resumo

55. Huang KC, Hsieh PH, Huang KC, et al. Vibrio necrotizing soft-tissue infection of the upper extremity: factors predictive of amputation and death. J Infect. 2008;57:290-297. Resumo

56. Chen S, Chan K, Chao W, et al. Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10 year retrospective study. Crit Care Med. 2010;38:1984-1990. Resumo

57. Hong GL, Dai XQ, Lu CJ, et al. Temporizing surgical management improves outcome in patients with Vibrio necrotizing fasciitis complicated with septic shock on admission. Burns. 2014;40:446-454. Resumo

58. Chen SC, Lee YT, Tsai SJ, et al. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother. 2012;67:488-493.Texto completo  Resumo

59. Centers for Disease Control and Prevention. Vibrio species causing vibriosis. Information for health professionals and laboratorians. June 2019 [internet publication].Texto completo

60. Neupane GP, Kim D. In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2010;29:407-410. Resumo

61. Tang H, Chen C, Lai C, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect. 2018;51:76-81.Texto completo  Resumo

62. Lin Y, Hung M, Chen C, et al. Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a child. J Microbiol Immunol Infect. 2016;49:138-141.Texto completo  Resumo

63. Chou TN, Lee YT, Lai YY, et al. Prognostic factors for primary septicemia and wound infection caused by Vibrio vulnificus. Am J Emerg Med. 2010;28:424-431. Resumo

64. Kuo SH, Tsai CF, Li CR, et al. Rapid Emergency Medicine Score as a main predictor of mortality in Vibrio vulnificus-related patients. Am J Emerg Med. 2013;31:1037-1041. Resumo

65. Lee YC, Hor LI, Chiu HY, et al. Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2014;33:1011-1018. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal